BMY
BRISTOL MYERS SQUIBB CO
NYSE: BMY · Princeton, NJ · Healthcare
$62.09+0.58 (+0.94%)Closed
Market Cap$126.79B
Cash$9.74Bmost recent
Runwayprofitable
P/E (TTM)17.9EPS $3.46
52-Wk Range$41.21 – $62.09
Avg Volume13.4M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$62.09+50.5%
Pipeline

Drug candidates sponsored by BRISTOL MYERS SQUIBB · ClinicalTrials.gov

75 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Irbesartan
Metabolic Syndrome+2 more
Completed
2007-06past
2
Phase 4Caffeine
Transplant Rejection
Completed
2013-04past
1
Phase 4Luspatercept
Anemia+1 more
Active, not recruiting
2028-12-16
2
Phase 4Nivolumab + Relatlimab
Untreated Melanoma+2 more
Not yet recruiting
2029-05-26
1
Phase 3Dasatinib
Myeloid Leukemia, Chronic+3 more
Completed
2009-12past
3
Phase 3ipilimumab
High Risk Stage III Melanoma+4 more
Completed
2014-07past
5
Phase 3Daclatasvir
Hepatitis C
Completed
2014-08past
2
Phase 3abatacept
Rheumatoid Arthritis (RA)+2 more
Completed
2019-04-02past
3
Phase 3Nivolumab
Brain Cancer+7 more
Completed
2025-04-16past
7
Phase 3KarXT
Bipolar-I Disorder With Mania or Mania With Mixed Features+2 more
Recruiting
2026-11-01
3
Phase 2Iza-bren
Non-Small Cell Lung Cancer
Recruiting
2028-12-15
1
Phase 3BMS-986278
Pulmonary Fibrosis
Not yet recruiting
2029-11-22
1
Phase 3Megestrol acetate
Anorexia+2 more
Completed—1
Phase 2Paclitaxel
Breast Cancer
Completed
2005-07past
1
Phase 2Entecavir
Hepatitis B Virus+1 more
Completed
2009-12past
1
Phase 2BMS-824393
Chronic Hepatitis C Virus Genotype 1
Withdrawn
2010-12past
1
Phase 2brivanib
Advanced Non-small Cell Lung Cancer+4 more
Completed
2012-02past
1
Phase 1BMS-908662
Colorectal Cancer+1 more
Completed
2012-11past
2
Phase 2SAR302503
Hematopoietic Neoplasm
Completed
2014-04past
1
Phase 2BMS-791325
Hepatitis C Virus
Completed
2015-02past
2
Phase 2HNO Donor
Heart Failure+2 more
Completed
2019-05-10past
1
Phase 2BMS-986165
Psoriasis+2 more
Completed
2019-11-19past
4
Phase 1BMS-986156
Solid Tumors
Completed
2019-12-16past
1
Phase 1BMS-813160
Colorectal Cancer+1 more
Completed
2023-04-06past
1
Phase 1BMS-986466
Advanced Solid Tumors
Terminated
2024-05-13past
1
Phase 1Relatlimab
Neoplasms by Site
Completed
2024-05-22past
1
Phase 1BMS-986408
Advanced Solid Tumors
Completed
2024-08-22past
1
Phase 1BMS-986507
Lung Cancer+1 more
Recruiting
2031-02-26
1
Phase 2HIV Integrase Inhibitor (BMS-707035)
HIV Infections
Withdrawn—1
Phase 2KOS-862
Lung Cancer
Terminated—1
Phase 1BMS-582664
Gastrointestinal Neoplasms
Terminated
2006-12past
1
Phase 1belatacept
Transplantation
Completed
2008-08past
1
Phase 1Vinflunine
Cancer
Withdrawn
2008-11past
1
Phase 1Alvespimycin
Solid Tumor+1 more
Completed
2009-08past
1
Phase 1MDX-1106
Carcinoma, Non-Small-Cell Lung+4 more
Completed
2009-11past
1
Phase 1BMS-816336
Diabetes Mellitus, Non-Insulin-Dependent+1 more
Completed
2010-02past
1
Phase 1Donepezil
Alzheimer Disease
Completed
2010-04past
1
Phase 1BMS-754807 (IGR-IR/IR Inhibitor)
Healthy Volunteers
Completed
2012-04past
1
Phase 1Ipilimumab, 3 mg
Non-Small Cell Lung Cancer
Completed
2013-06past
1
Phase 1ND-L02-s0201 Injection
Healthy
Completed
2014-02past
1
Phase 15-FU
Gastro-Intestinal Cancer
Completed
2014-06past
1
Phase 1Denenicokin
Neoplasms by Site
Completed
2014-12past
1
Phase 1BMS-936558 (Anti-PD-1)
Renal Cell Carcinoma
Completed
2014-12-01past
1
Phase 1Anti-PDL-1 antibody
Cancer, Multiple Indications
Completed
2015-07past
1
Phase 1BMS-986141
Ischemic Stroke
Completed
2016-11past
1
Phase 1Process E Belatacept
Renal Transplantation
Completed
2017-01-27past
1
Phase 1BMS-986012
Small Cell Lung Cancer
Completed
2017-08-29past
1
Phase 1BMS-986231 Formulation A
Heart Failure
Completed
2019-07-29past
1
Phase 1BMS-986231
Liver Dysfunction+6 more
Completed
2019-08-29past
1
Phase 1BMS-986263
Hepatic Impairment
Completed
2021-06-01past
1
Phase 1Deucravacitinib
Healthy Participants
Completed
2022-01-03past
1
Phase 1BMS-986166
Healthy Volunteers
Completed
2022-02-07past
1
Phase 1Methotrexate
Healthy Participants
Completed
2022-11-17past
1
Phase 1BMS-986196
Healthy Adult Volunteers
Withdrawn
2023-11-30past
1
Phase 1BMS-986322
Healthy Participants
Completed
2023-12-13past
1
Phase 1BMS-986435
Healthy Volunteers
Recruiting
2026-12-17
1
Phase 1BMS-986504
Advanced Solid Tumors With Homozygous MTAP Deletion
Recruiting
2027-10-25
1
N/AUnnamed
Rheumatoid Arthritis
Completed
2010-07past
1
N/AImatinib
Leukemia, Myeloid, Chronic-Phase (CML-CP)
Completed
2013-01past
1
N/ANo Intervention
HIV-1
Completed
2016-03past
1
N/AUnnamed
Chronic Hepatitis C
Completed
2017-01-20past
1
N/AUnnamed
Rheumatoid Arthritis
Completed
2019-03-29past
1
N/AUnnamed
Renal Cell Carcinoma
Completed
2020-07-13past
1
N/AUnnamed
Multiple Myeloma
Withdrawn
2022-10-28past
1
N/ASystemic therapy
Peripheral T-cell Lymphoma
Completed
2025-02-05past
1
N/AElotuzumab in combination with pomalidomide and dexamethasone
Relapsed or Refractory Multiple Myeloma
Completed
2025-03-17past
1
N/AUnnamed
Lung Cancer
Completed
2025-04-18past
1
N/AUnnamed
Head and Neck Cancer
Completed
2025-04-28past
1
N/AUnnamed
Psoriasis
Completed
2025-05-28past
1
N/AErythropoiesis-stimulating agents (ESAs)
Lower-risk Myelodysplastic Syndromes (TD LR-MDS)
Active, not recruiting
2026-03-31past
1
N/AUnnamed
Non-Small Cell Lung Cancer
Active, not recruiting
2026-12-31
1
N/AMavacamten
Breastfeeding+3 more
Recruiting
2027-04-30
2
N/AUnnamed
Juvenile Idiopathic Arthritis
Active, not recruiting
2029-01-02
1
N/ABET Inhibitor
n/a
No Longer Available—1
N/ANystatin
Candidiasis, Oral+1 more
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for BMY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.